XML 48 R19.htm IDEA: XBRL DOCUMENT

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On August 7, 2015, The Company entered into a license and collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Under the agreement, MedImmune will acquire exclusive rights to the Company's INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18. Under the terms of the agreement, MedImmune will make an upfront payment of $27.5 million to the Company as well as potential future payments upon reaching development and commercial milestones totaling up to $700 million. MedImmune will fund all development costs. The Company is entitled to receive up to double-digit tiered royalties on INO-3112 product sales. Within the broader collaboration, the Company and MedImunne will develop up to two additional DNA-based cancer vaccine products not included in the Company's current product pipeline, which MedImmune will have the exclusive rights to develop and commercialize. The Company will receive development, regulatory and commercialization milestone payments and will be eligible to receive royalties on worldwide net sales for these additional cancer vaccine products. Subsequent to June 30, 2015, warrants to purchase 306,625 shares of common stock were exercised for total proceeds to the Company of $1.6 million.